Trials / Not Yet Recruiting
Not Yet RecruitingNCT06764251
Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma
A Single-centre Phase II Clinical Study of Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Liaoning Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the efficacy of neoadjuvant long-term treatment with tislelizumab in combination with SOX in the treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab + SOX | tislelizumab combined with SOX |
Timeline
- Start date
- 2024-12-30
- Primary completion
- 2027-12-31
- Completion
- 2028-03-31
- First posted
- 2025-01-08
- Last updated
- 2025-01-08
Source: ClinicalTrials.gov record NCT06764251. Inclusion in this directory is not an endorsement.